Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorÜnalp, Aycan
dc.contributor.authorGüzin, Yiğithan
dc.contributor.authorÜnay, Bülent
dc.contributor.authorTosun, Ayşe
dc.contributor.authorÇavuşoğlu, Dilek
dc.contributor.authorGazeteci Tekin, Hande
dc.contributor.authorHız Kurul, Semra
dc.contributor.authorArhan, Ebru
dc.contributor.authorEdizer, Selvinaz
dc.contributor.authorÖztürk, Gülten
dc.contributor.authorYiş, Uluç
dc.contributor.authorYılmaz, Ünsal
dc.contributor.authorTürk Nadir Epilepsiler Çalışma Grubu
dc.date.accessioned2023-10-12T10:37:59Z
dc.date.available2023-10-12T10:37:59Z
dc.date.issued2023en_US
dc.identifier.citationÜnalp, A., Güzin, Y., Ünay, B., Tosun, A., Çavuşoğlu, D., Tekin, H. G., ... & Turkish Rare Epilepsies Study Group. (2023). Clinical and genetic evaluations of rare childhood epilepsies in Turkey's national cohort. Epileptic Disorders.en_US
dc.identifier.issn1950-6945
dc.identifier.urihttps://dx.doi.org/10.1002/epd2.20150.
dc.identifier.urihttps://hdl.handle.net/20.500.12933/1637
dc.description.abstractAbstract Objective: As new-generation sequencing methods develop, rare epilepsy is increasing and burdening national health systems-community building among rare epilepsies fuels collaboration, research, and resource development. Comorbidities should be carefully considered in diagnosing and treating children with rare epilepsy. This multicentric study aimed to evaluate the clinical features and comorbidities of children diagnosed with rare childhood genetic epilepsies. Methods: This multicentric study evaluated demographics, clinical findings, neuromotor developmental progress, and concomitant comorbid diseases of childhood rare genetic epilepsies. We included 156 patients from the nine tertiary health centers in our research. Results: The gene variants were distributed to 36 patients (23.1%) with SCN1A, 14 (9%) with KCNQ2, 10 (6.4%) with PCDH19, 6 (3.8%) with SCN8A, 5 (3.2%) with SLC2A1, 5 (3.2%) with WWOX, respectively. The remaining 80 patients (51.3%) were with other gene variants. Comorbid conditions are present in 82% of patients, most commonly intellectual disability (70%), developmental delay (32.1%), and movement disorders 12.8%. Most of the rare genetic epileptic children (52%) were using more than three anti-seizure drugs. In terms of developmental delay in children with rare epilepsy, the neuromotor developmental delay was found to progress with age, shown at the end of 2nd year of treatment. In addition, comorbidity, number of drugs, multiple types of seizures, seizure frequency, age at diagnosis of epilepsy, and duration of epilepsy all affected neuromotor developmental status (p < .05). Significance: Despite using multiple antiseizure medications, most of our patients had drug-resistant epilepsy and concomitant developmental delay. Since a complete cure cannot be achieved in most of these patients further studies with centers' collaboration might help improve therapeutic decisions and precision treatment methods.en_US
dc.language.isoengen_US
dc.publisher[Hoboken]en_US
dc.relation.isversionof10.1002/epd2.20150.en_US
dc.rightsinfo:eu-repo/semantics/embargoedAccessen_US
dc.subjectChildhooden_US
dc.subjectComorbidityen_US
dc.subjectGeneticen_US
dc.subjectPrecision Medicineen_US
dc.subjectRare Epilepsyen_US
dc.titleClinical and genetic evaluations of rare childhood epilepsies in Turkey's national cohorten_US
dc.typearticleen_US
dc.authorid0000-0003-4924-5300en_US
dc.departmentAFSÜen_US
dc.contributor.institutionauthorÇavuşoğlu, Dilek
dc.relation.journalEpileptic disorders : international epilepsy journal with videotapeen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster